
Palvella Therapeutics Secures New U.S. Patent for QTORIN Rapamycin
WAYNE, PA — Palvella Therapeutics, Inc. (Nasdaq: PVLA) has secured its fifth U.S. patent for QTORINâ„¢ 3.9% rapamycin anhydrous gel, reinforcing its position in the development of treatments for rare …
Palvella Therapeutics Secures New U.S. Patent for QTORIN Rapamycin Read More